Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2012 - 11 - 13

Menarini Press Release - Florence, 13th November 2012

Florence, 13th November 2012



Palazzo Vecchio, town hall of the city of Florence, welcomed over 180 oncologists and hematologists for the presentation of the Florence Trial, an international clinical trial conducted by the Menarini Group aimed at assessing the benefits of the drug Febuxostat in the prevention of tumor lysis syndrome.

FLORENCE stands for Febuxostat for tumor Lysis syndrOme pREvention iN haematologiC malignanciEs which pays tribute to the city where Menarini’s headquarters are located. The trial was presented at Palazzo Vecchio in March during a press conference in the presence of Stefania Saccardi, City Councillor for Welfare.

Tumor lysis syndrome is a severe and relatively common complication which occurs during chemotherapy in subjects with leukemia and lymphoma. It is characterized by the onset of rapid and serious hyperuricemia and electrolyte imbalance which can, in turn, lead to renal failure and cardiac and neurological disorders with possibly fatal consequences.

In the Florence trial, Febuxustat faces a double challenge: the prevention of hyperuricemia and kidney damage,said Michele Spina, International Coordinator of the Florence Trial and Co-Director of the Division of Medical Oncology at the National Cancer Institute in Aviano. “The current paradox facing hematologists the treatment of leukemia and lymphoma is that there are effective chemotherapies that can cure but there are no adequate support therapies that protect from the damages of the chemotherapy itself. Studies like this are more than welcome and are no less important in the research of innovative anti-tumor therapies”.

Italy heads the study with 10 centers of excellence for the treatment of hematologic malignancies, initiating the enrollment phase of its first patients.

“For Menarini and its researchers, the investigator meeting is the occasion to lay the foundation stone for the study’s initiation. Our clinical trial will serve as ambassador of the name “Florence” throughout the world given that it will take place in 12 countries of the European Union and Eastern Europe, also including the Russian Federation and Brazil, and will involve the participation of over 300 patients with lymphoma and/or leukemia,” said Dr. Carlo Alberto Maggi, Director of Research of the Menarini Group.

President of Confindustria Firenze, Simone Bettini commented: "Menarini’s project is proof that Florence is a dynamic city full of professional know-how and this includes the pharmaceutical sector which represents excellence at the International level for its quality of applied research and continuous innovation. We are one of the three Italian poles of the pharmaceutical industry and the entire territory must focus even more on this sector that invests and creates wealth and employment in a highly specialized area. The sector contributes to the international positioning of Florence and we must be able to collaborate with it and increase its competitiveness.